Bluejay net loss widens to $2.32 million in Q2 FY26

Reuters2026/08/12 20:12

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Bluejay Diagnostics posted a net loss of USD 2.32 million for the quarter ended June 30, 2026, widening from USD 1.96 million.
Operating loss widened to USD 2.35 million from USD 1.99 million, as operating expenses rose to USD 2.35 million.
Research and development expense climbed to USD 1.44 million from USD 889,896, driven by higher clinical development costs.
General and administrative expense fell to USD 911,318 from USD 1.1 million on lower legal and accounting fees.
Cash and cash equivalents totaled USD 9.6 million at June 30, 2026; cash runway seen through the second quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bluejay Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-088347), on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Bluejay net loss widens to $2.32 million in Q2 FY26

You may also like

Crypto prices